A new trading day began on Tuesday, with Cytokinetics Inc (NASDAQ: CYTK) stock price up 2.52% from the previous day of trading, before settling in for the closing price of $43.31. CYTK’s price has ranged from $40.53 to $75.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 44.31% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -8.09%. With a float of $115.40 million, this company’s outstanding shares have now reached $118.21 million.
In an organization with 498 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -890.46%, operating margin of -2902.72%, and the pretax margin is -3191.11%.
Cytokinetics Inc (CYTK) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cytokinetics Inc is 2.54%, while institutional ownership is 109.87%. The most recent insider transaction that took place on Mar 06 ’25, was worth 144,565. In this transaction EVP, Chief Commercial Officer of this company sold 3,341 shares at a rate of $43.27, taking the stock ownership to the 64,434 shares. Before that another transaction happened on Mar 06 ’25, when Company’s EVP Research & Development sold 8,228 for $43.27, making the entire transaction worth $356,026. This insider now owns 105,394 shares in total.
Cytokinetics Inc (CYTK) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.4 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -8.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.98% during the next five years compared to -20.02% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Here are Cytokinetics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 284.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.28, a number that is poised to hit -1.37 in the next quarter and is forecasted to reach -4.61 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Let’s dig in a bit further. During the last 5-days, its volume was 1.55 million. That was inferior than the volume of 1.6 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 26.94%. Additionally, its Average True Range was 2.57.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 20.52%, which indicates a significant decrease from 25.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.39% in the past 14 days, which was higher than the 47.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $46.67, while its 200-day Moving Average is $51.94. However, in the short run, Cytokinetics Inc’s stock first resistance to watch stands at $45.53. Second resistance stands at $46.65. The third major resistance level sits at $48.40. If the price goes on to break the first support level at $42.66, it is likely to go to the next support level at $40.91. The third support level lies at $39.79 if the price breaches the second support level.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
With a market capitalization of 5.26 billion, the company has a total of 118,411K Shares Outstanding. Currently, annual sales are 18,470 K while annual income is -589,530 K. The company’s previous quarter sales were 16,930 K while its latest quarter income was -150,020 K.
